ERBB2 and breast cancer: The authors also note that new agents have been approved in China for HR+/HER2(−) breast cancer since the survey study was conducted (detailed in Supplementary Table 1), including abemaciclib, tucidinostat (chidamide), utidelone, dalpiciclib, and envafolimab [21–23, 25, 26].